The content on this site is intended for healthcare professionals only
Dr De Azambuja reviews data released at ESMO 2016 relating to the use of PARP inhibitor niraparib in platinum-sensitive recurrent ovarian cancer.
Read the news story or watch the interview or press conference with the investigator himself, Dr Mansoor Raza Mirza, for more.
Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas
Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
